{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:54:24Z","timestamp":1792853664511,"version":"4.5.0"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semcancer.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T21:13:35Z","timestamp":1680815615000},"page":"45-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Obesity and multiple myeloma: Emerging mechanisms and perspectives"],"prefix":"10.1016","volume":"92","author":[{"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2023.04.003_bib1","unstructured":"Centers for Disease Control and Prevention. Adult Obesity Facts. Accessed March 13, 2023. \u3008https:\/\/www.cdc.gov\/obesity\/data\/adult.html\u3009."},{"key":"10.1016\/j.semcancer.2023.04.003_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bluher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib5","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib6","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.semcancer.2023.04.003_bib7","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2014.58.4680","article-title":"American Society of Clinical Oncology position statement on obesity and cancer","volume":"32","author":"Ligibel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/bmt.2014.71","article-title":"The skinny on obesity and plasma cell myeloma: a review of the literature","volume":"49","author":"Carson","year":"2014","journal-title":"Bone Marrow Transpl."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41375-021-01443-7","article-title":"A comprehensive review of the impact of obesity on plasma cell disorders","volume":"36","author":"Parikh","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.32109","article-title":"Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies","volume":"145","author":"Psaltopoulou","year":"2019","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ijc.31330","article-title":"Alcohol consumption and risk of hematological malignancies: a meta-analysis of prospective studies","volume":"143","author":"Psaltopoulou","year":"2018","journal-title":"Int J. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib12","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1080\/10428194.2018.1563693","article-title":"Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies","volume":"60","author":"Sergentanis","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/01635581.2018.1490444","article-title":"Micronutrient intake and risk of hematological malignancies in adults: a systematic review and meta-analysis of cohort studies","volume":"70","author":"Psaltopoulou","year":"2018","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.semcancer.2023.04.003_bib14","unstructured":"World Health Association. Obesity and overweight. Accessed March 13, 2023. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\u3009."},{"key":"10.1016\/j.semcancer.2023.04.003_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","article-title":"The epidemiology of obesity","volume":"92","author":"Chooi","year":"2019","journal-title":"Metabolism"},{"issue":"10113","key":"10.1016\/j.semcancer.2023.04.003_bib16","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2023.04.003_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"21","key":"10.1016\/j.semcancer.2023.04.003_bib19","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the american heart association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41366-018-0210-2","article-title":"Impact of overweight, obesity and severe obesity on life expectancy of Australian adults","volume":"43","author":"Lung","year":"2019","journal-title":"Int J. Obes. (Lond. )"},{"issue":"i-xii","key":"10.1016\/j.semcancer.2023.04.003_bib21","first-page":"1","article-title":"Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organ Tech. Rep. Ser."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jval.2016.02.008","article-title":"Estimating the medical care costs of obesity in the united states: systematic review, meta-analysis, and empirical analysis","volume":"19","author":"Kim","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.maturitas.2011.04.005","article-title":"Economic costs of adult obesity: a review of recent European studies with a focus on subgroup-specific costs","volume":"69","author":"von Lengerke","year":"2011","journal-title":"Maturitas"},{"issue":"17","key":"10.1016\/j.semcancer.2023.04.003_bib24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"New Engl. J. Med"},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1634\/theoncologist.2010-0206","article-title":"Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma","volume":"15","author":"Lichtman","year":"2010","journal-title":"Oncologist"},{"issue":"9612","key":"10.1016\/j.semcancer.2023.04.003_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.semcancer.2023.04.003_bib28","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood.2019846782","article-title":"Monoclonal gammopathy of undetermined significance","volume":"133","author":"Mouhieddine","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2010-01-262394","article-title":"Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib31","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.semcancer.2023.04.003_bib32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clml.2021.01.008","article-title":"Overweight\/obesity and monoclonal gammopathy of undetermined significance","volume":"21","author":"Georgakopoulou","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib35","first-page":"626","article-title":"Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study","volume":"89","author":"Thompson","year":"2004","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib36","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00256-016-2425-4","article-title":"Abdominal adipose tissue in MGUS and multiple myeloma","volume":"45","author":"Veld","year":"2016","journal-title":"Skelet. Radio."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib37","first-page":"35","article-title":"Obesity and cancer risk among white and black United States veterans","volume":"15","author":"Samanic","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"7630","key":"10.1016\/j.semcancer.2023.04.003_bib38","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/bmj.39367.495995.AE","article-title":"Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study","volume":"335","author":"Reeves","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/01.ede.0000172135.61188.2d","article-title":"Anthropometric characteristics and risk of multiple myeloma","volume":"16","author":"Blair","year":"2005","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/aje\/kwj353","article-title":"Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women","volume":"165","author":"Engeland","year":"2007","journal-title":"Am. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib41","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ejca.2008.11.004","article-title":"Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins","volume":"45","author":"Soderberg","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib42","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/aje\/kwq085","article-title":"Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","volume":"171","author":"Troy","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib43","first-page":"117","article-title":"Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States","volume":"12","author":"Brown","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","article-title":"Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the international multiple myeloma consortium (IMMC)","volume":"26","author":"Birmann","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib45","first-page":"901","article-title":"Relation of body mass index to cancer risk in 362,552 Swedish men","volume":"17","author":"Samanic","year":"2006","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib46","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/0008-5472.CAN-07-0274","article-title":"Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden","volume":"67","author":"Fernberg","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/aje\/kwp123","article-title":"Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study","volume":"170","author":"Pylypchuk","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"11","key":"10.1016\/j.semcancer.2023.04.003_bib48","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3324\/haematol.13078","article-title":"Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"93","author":"Britton","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib49","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1055-9965.EPI-10-0171","article-title":"Association of anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a Japanese population: a population-based cohort study","volume":"19","author":"Kanda","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/EDE.0b013e3181cc9241","article-title":"Anthropometric characteristics and multiple myeloma risk","volume":"21","author":"Lu","year":"2010","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3535","article-title":"Diabetes mellitus and multiple myeloma; common features of two distinct entities","volume":"38","author":"Tentolouris","year":"2022","journal-title":"Diabetes Metab. Res Rev."},{"issue":"15","key":"10.1016\/j.semcancer.2023.04.003_bib52","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib53","first-page":"CD008664","article-title":"Thalidomide for managing cancer cachexia","volume":"2012","author":"Reid","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib54","first-page":"381","article-title":"Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group","volume":"13","author":"Jatoi","year":"2005","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib55","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.18632\/oncotarget.14576","article-title":"Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet","volume":"8","author":"Myers","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib56","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2023.04.003_bib57","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.2147\/OTT.S227166","article-title":"Clinical utility of selinexor\/dexamethasone in patients with relapsed or refractory multiple myeloma: a review of current evidence and patient selection","volume":"13","author":"Malandrakis","year":"2020","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.semcancer.2023.04.003_bib58","doi-asserted-by":"crossref","first-page":"4812637","DOI":"10.1155\/2017\/4812637","article-title":"The evolution of prognostic factors in multiple myeloma","volume":"2017","author":"Hanbali","year":"2017","journal-title":"Adv. Hematol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib59","first-page":"575","article-title":"Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study","volume":"7","author":"Khan","year":"2006","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.12935","article-title":"Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies","volume":"166","author":"Teras","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw120","article-title":"Multiple myeloma mortality in relation to obesity among African Americans","volume":"108","author":"Sonderman","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1634\/theoncologist.2013-0015","article-title":"Influence of body mass index on survival in veterans with multiple myeloma","volume":"18","author":"Beason","year":"2013","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.semcancer.2023.04.003_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215331","article-title":"Body mass index and overall survival of patients with newly diagnosed multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41408-022-00782-7","article-title":"Extreme body mass index and survival in newly diagnosed multiple myeloma patients","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2023.04.003_bib65","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2020.38.15_suppl.8543","article-title":"FDA analysis: impact of BMI on ef\ufb01cacy outcomes in multiple myeloma trials","volume":"38","author":"Ershler","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib66","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.clml.2017.03.252","article-title":"Influence of obesity on outcomes of patients with relapsed refractory multiple myeloma","volume":"17","author":"Roy","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib67","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","article-title":"The importance of body composition in explaining the overweight paradox in cancer-counterpoint","volume":"78","author":"Caan","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2023.04.003_bib68","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-023-00497-1","article-title":"Obesity paradox: fact or fiction","author":"Simati","year":"2023","journal-title":"Curr. Obes. Rep."},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib69","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2011.05.005","article-title":"Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"17","author":"Vogl","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41409-020-01008-9","article-title":"Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation","volume":"56","author":"Williams","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.semcancer.2023.04.003_bib71","article-title":"Outcomes of autologous hematopoietic stem cell transplantation depending on body-mass index in patients with multiple myeloma","author":"Maiia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2023.04.003_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.578966","article-title":"Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases","volume":"11","author":"Recinella","year":"2020","journal-title":"Front Physiol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103570","article-title":"Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications","volume":"21","author":"Zorena","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"69","key":"10.1016\/j.semcancer.2023.04.003_bib74","article-title":"The unique metabolic characteristics of bone marrow adipose tissue","volume":"10","author":"Li","year":"2019","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/nu13051412","article-title":"Bone marrow adipocytes-role in physiology and various nutritional conditions in human and animal models","volume":"13","author":"Piotrowska","year":"2021","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094462","article-title":"The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.semcancer.2023.04.003_bib77","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib78","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41416-021-01371-4","article-title":"Myeloma-bone marrow adipocyte axis in tumour survival and treatment response","volume":"125","author":"Jafari","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2023.04.003_bib79","article-title":"Development and characterization of three cell culture systems to investigate the relationship between primary bone marrow adipocytes and myeloma cells","volume":"12","author":"Fairfield","year":"2022","journal-title":"Front Oncol."},{"issue":"67","key":"10.1016\/j.semcancer.2023.04.003_bib80","article-title":"Signaling interplay between bone marrow adipose tissue and multiple myeloma cells","volume":"7","author":"Falank","year":"2016","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"11","key":"10.1016\/j.semcancer.2023.04.003_bib81","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib82","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","article-title":"Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells","volume":"21","author":"Caers","year":"2007","journal-title":"Leukemia"},{"issue":"33","key":"10.1016\/j.semcancer.2023.04.003_bib83","doi-asserted-by":"crossref","first-page":"34329","DOI":"10.18632\/oncotarget.6020","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib84","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype","volume":"81","author":"Fairfield","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib85","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/er.2011-1015","article-title":"The role of adiponectin in cancer: a review of current evidence","volume":"33","author":"Dalamaga","year":"2012","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/hmbci-2015-0016","article-title":"Adiponectin as a biomarker linking obesity and adiposopathy to hematologic malignancies","volume":"23","author":"Dalamaga","year":"2015","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.semcancer.2023.04.003_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2018.05.033","article-title":"The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention","volume":"53","author":"Allegra","year":"2018","journal-title":"Eur. J. Intern Med"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib88","first-page":"193","article-title":"Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study","volume":"20","author":"Dalamaga","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib89","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/oby.21894","article-title":"Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease","volume":"25","author":"Hofmann","year":"2017","journal-title":"Obes. (Silver"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12902-022-00939-2","article-title":"Importance of circulating adipocytokines in multiple myeloma: a systematic review and meta-analysis based on case-control studies","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Endocr. Disord."},{"issue":"22","key":"10.1016\/j.semcancer.2023.04.003_bib91","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1182\/blood-2012-06-438606","article-title":"A prospective study of circulating adipokine levels and risk of multiple myeloma","volume":"120","author":"Hofmann","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib92","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-15-2406","article-title":"Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals","volume":"76","author":"Hofmann","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib93","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1600-0609.2009.01311.x","article-title":"Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma","volume":"83","author":"Reseland","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"22","key":"10.1016\/j.semcancer.2023.04.003_bib94","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib95","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.4049\/jimmunol.178.6.3511","article-title":"Identification of adiponectin as a novel hemopoietic stem cell growth factor","volume":"178","author":"DiMascio","year":"2007","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib96","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.4049\/jimmunol.171.10.5091","article-title":"Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells","volume":"171","author":"Yokota","year":"2003","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib97","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41556-022-00909-9","article-title":"Adiponectin receptors sustain haematopoietic stem cells throughout adulthood by protecting them from inflammation","volume":"24","author":"Meacham","year":"2022","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib98","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jmcb\/mjw012","article-title":"Adiponectin: a versatile player of innate immunity","volume":"8","author":"Luo","year":"2016","journal-title":"J. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib99","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1002\/cncr.11072","article-title":"A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications","volume":"97","author":"Lauta","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib100","doi-asserted-by":"crossref","first-page":"R1220","DOI":"10.1152\/ajpregu.00397.2004","article-title":"Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes","volume":"288","author":"Ajuwon","year":"2005","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib101","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/jbmr.3951","article-title":"Myeloma cells down-regulate adiponectin in bone marrow adipocytes via TNF-alpha","volume":"35","author":"Morris","year":"2020","journal-title":"J. Bone Min. Res"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib102","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bbrc.2004.08.145","article-title":"Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes","volume":"323","author":"Wolf","year":"2004","journal-title":"Biochem Biophys. Res Commun."},{"issue":"22","key":"10.1016\/j.semcancer.2023.04.003_bib103","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1182\/blood-2011-10-379834","article-title":"Adipokines in MM: time to trim the fat","volume":"118","author":"Dhodapkar","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib104","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2014.112","article-title":"PKA\/AMPK signaling in relation to adiponectin's antiproliferative effect on multiple myeloma cells","volume":"28","author":"Medina","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib105","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"2 Pt B","key":"10.1016\/j.semcancer.2023.04.003_bib106","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.canlet.2014.09.050","article-title":"Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models","volume":"356","author":"Zi","year":"2015","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib107","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semcancer.2023.04.003_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155185","article-title":"Investigating the vascular toxicity outcomes of the irreversible proteasome inhibitor carfilzomib","volume":"21","author":"Efentakis","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2023.04.003_bib109","unstructured":"Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma. Accessed March 13, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04850846."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology: emerging clinical applications","volume":"152","author":"Kelesidis","year":"2010","journal-title":"Ann. Intern Med"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062870","article-title":"Leptin and cancer: updated functional roles in carcinogenesis, therapeutic niches, and developments","volume":"22","author":"Lin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib112","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/172460080401900107","article-title":"Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines","volume":"19","author":"Alexandrakis","year":"2004","journal-title":"Int J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib113","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1677\/erc.1.01169","article-title":"Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways","volume":"13","author":"Sharma","year":"2006","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib114","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1038\/leu.2017.146","article-title":"Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma","volume":"31","author":"Favreau","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4030026","article-title":"Leptin-induced JAK\/STAT signaling and cancer growth","volume":"4","author":"Mullen","year":"2016","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib116","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.4049\/jimmunol.1200935","article-title":"Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses","volume":"189","author":"Procaccini","year":"2012","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib117","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3892\/or.2015.4198","article-title":"Differential crosstalk between the AMPK and PI3K\/Akt pathways in breast cancer cells of differing genotypes: leptin inhibits the effectiveness of AMPK activation","volume":"34","author":"El-Masry","year":"2015","journal-title":"Oncol. Rep."},{"issue":"52","key":"10.1016\/j.semcancer.2023.04.003_bib118","doi-asserted-by":"crossref","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.semcancer.2023.04.003_bib119","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1111\/febs.15322","article-title":"Resistin in metabolism, inflammation, and disease","volume":"287","author":"Tripathi","year":"2020","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib120","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bjc.2017.282","article-title":"Circulating resistin levels and risk of multiple myeloma in three prospective cohorts","volume":"117","author":"Santo","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib121","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","article-title":"Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression","volume":"102","author":"Pang","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib122","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/0008-5472.CAN-09-2465","article-title":"The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer","volume":"70","author":"Galli","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2023.04.003_bib123","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2018.01.001","article-title":"The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges","volume":"82","author":"Dalamaga","year":"2018","journal-title":"Metabolism"},{"issue":"18","key":"10.1016\/j.semcancer.2023.04.003_bib124","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2174\/092986708785133004","article-title":"Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions","volume":"15","author":"Adeghate","year":"2008","journal-title":"Curr. Med Chem."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib125","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2337\/diabetes.54.10.2911","article-title":"Plasma visfatin concentrations and fat depot-specific mRNA expression in humans","volume":"54","author":"Berndt","year":"2005","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.semcancer.2023.04.003_bib126","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/bph.13505","article-title":"Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine","volume":"173","author":"Grolla","year":"2016","journal-title":"Br. J. Pharm."},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib127","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.maturitas.2011.12.013","article-title":"Could serum visfatin be a potential biomarker for postmenopausal breast cancer","volume":"71","author":"Dalamaga","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.semcancer.2023.04.003_bib128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.peptides.2013.11.010","article-title":"Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women","volume":"51","author":"Li","year":"2014","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib129","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1111\/ajco.12090","article-title":"Association of plasma visfatin with risk of colorectal cancer: an observational study of Chinese patients","volume":"12","author":"Chen","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib130","first-page":"1112","article-title":"Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma","volume":"45","author":"Liu","year":"2020","journal-title":"Int J. Mol. Med"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib131","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.exphem.2013.02.008","article-title":"NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity","volume":"41","author":"Venkateshaiah","year":"2013","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib132","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2016.0401","article-title":"Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial","volume":"152","author":"Goldinger","year":"2016","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib133","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5114\/ceji.2020.103418","article-title":"Obesity and chronic inflammation crosslinking","volume":"45","author":"Artemniak-Wojtowicz","year":"2020","journal-title":"Cent. Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073587","article-title":"Immunological prognostic factors in multiple myeloma","volume":"22","author":"Bebnowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib136","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2012.10.014","article-title":"Tumor necrosis factor","volume":"328","author":"Chu","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2023.04.003_bib137","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000289203","article-title":"TNF-alpha and obesity","volume":"11","author":"Tzanavari","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib138","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM198708273170902","article-title":"Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells","volume":"317","author":"Garrett","year":"1987","journal-title":"New Engl. J. Med"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib139","first-page":"52","article-title":"Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma","volume":"20","author":"Filella","year":"1996","journal-title":"Cancer Detect Prev."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib140","first-page":"65","article-title":"Tumor necrosis factor is a survival and proliferation factor for human myeloma cells","volume":"10","author":"Jourdan","year":"1999","journal-title":"Eur. Cytokine Netw."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib141","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/onc.2016.309","article-title":"Non-canonical NFkappaB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB:p50 NFkappaB pathway","volume":"36","author":"Roy","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib142","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","article-title":"Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma","volume":"100","author":"Neben","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib143","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-1053-03","article-title":"Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1","volume":"10","author":"Johrer","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2023.04.003_bib144","first-page":"12","article-title":"Ma D. TNF-alpha, a good or bad factor in hematological diseases?","volume":"1","author":"Tian","year":"2014","journal-title":"Stem Cell Invest."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/10428190290006224","article-title":"Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma","volume":"43","author":"Dmoszynska","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib146","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2005.05.006","article-title":"Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion","volume":"29","author":"Kast","year":"2005","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib147","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0145-2126(02)00082-6","article-title":"Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leuk. Res"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib148","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.2011.04219.x","article-title":"Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum","volume":"37","author":"Shareef","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094282","article-title":"B Lymphocyte Stimulator (BLyS) is expressed in human adipocytes in vivo and is related to obesity but not to insulin resistance","volume":"9","author":"Muller","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2023.04.003_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155271","article-title":"Cytokine profile in multiple myeloma","volume":"136","author":"Jasrotia","year":"2020","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.semcancer.2023.04.003_bib151","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2012.03.012","article-title":"Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma","volume":"36","author":"Fragioudaki","year":"2012","journal-title":"Leuk. Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib152","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3892\/ol.2017.6528","article-title":"Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol. Lett."},{"issue":"19","key":"10.1016\/j.semcancer.2023.04.003_bib153","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2023.04.003_bib154","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/389579","article-title":"Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma","volume":"2013","author":"Alexandrakis","year":"2013","journal-title":"Biomed. Res Int"},{"issue":"1\u20133","key":"10.1016\/j.semcancer.2023.04.003_bib155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12026-014-8528-x","article-title":"Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma","volume":"59","author":"Rosean","year":"2014","journal-title":"Immunol. Res"},{"key":"10.1016\/j.semcancer.2023.04.003_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155358","article-title":"Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels","volume":"138","author":"Gu","year":"2021","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib157","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.2830390303","article-title":"Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma","volume":"39","author":"Solary","year":"1992","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib158","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1365-2141.1996.4721018.x","article-title":"Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma","volume":"93","author":"Kyrtsonis","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.semcancer.2023.04.003_bib159","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R","article-title":"The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma","volume":"82","author":"Stasi","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib160","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.4049\/jimmunol.132.6.2948","article-title":"Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line","volume":"132","author":"Yoshizaki","year":"1984","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib161","doi-asserted-by":"crossref","first-page":"20394","DOI":"10.18632\/oncotarget.14610","article-title":"Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression","volume":"8","author":"Mondello","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib162","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.semcancer.2023.04.003_bib163","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"20","key":"10.1016\/j.semcancer.2023.04.003_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011137","article-title":"Insulin resistance and cancer: in search for a causal link","volume":"22","author":"Chiefari","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib165","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1042\/BCJ20210134","article-title":"Insulin and cancer: a tangled web","volume":"479","author":"Leitner","year":"2022","journal-title":"Biochem J."},{"issue":"11","key":"10.1016\/j.semcancer.2023.04.003_bib166","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/leu.2010.192","article-title":"Insulin is a potent myeloma cell growth factor through insulin\/IGF-1 hybrid receptor activation","volume":"24","author":"Sprynski","year":"2010","journal-title":"Leukemia"},{"issue":"30","key":"10.1016\/j.semcancer.2023.04.003_bib167","doi-asserted-by":"crossref","first-page":"48732","DOI":"10.18632\/oncotarget.8982","article-title":"The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential","volume":"7","author":"Bieghs","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2023.04.003_bib168","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/789174","article-title":"Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms","volume":"2012","author":"Arcidiacono","year":"2012","journal-title":"Exp. Diabetes Res"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib169","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood.V93.1.235","article-title":"Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells","volume":"93","author":"Vanderkerken","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib170","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250","article-title":"Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines","volume":"88","author":"Georgii-Hemming","year":"1996","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib171","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.bjc.6601613","article-title":"Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model","volume":"90","author":"Menu","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib172","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.fertnstert.2005.10.054","article-title":"Obesity and androgens: facts and perspectives","volume":"85","author":"Pasquali","year":"2006","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.semcancer.2023.04.003_bib173","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1476-4598-6-59","article-title":"Estrogenic or antiestrogenic therapies for multiple myeloma","volume":"6","author":"Sola","year":"2007","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib174","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/10428194.2018.1538511","article-title":"Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC","volume":"60","author":"Ozerova","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2023.04.003_bib175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fonc.2018.00103","article-title":"The relation of obesity-related hormonal and cytokine levels with multiple myeloma and non-hodgkin lymphoma","volume":"8","author":"Hosgood","year":"2018","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib176","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1182\/blood-2002-02-0376","article-title":"2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells","volume":"100","author":"Chauhan","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2023.04.003_bib177","first-page":"3948","article-title":"Promising preclinical activity of 2-methoxyestradiol in multiple myeloma","volume":"8","author":"Dingli","year":"2002","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib178","first-page":"1434","article-title":"Estrogen receptors in human myeloma cells","volume":"60","author":"Otsuki","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib179","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V92.5.1749","article-title":"Anti-estrogens induce apoptosis of multiple myeloma cells","volume":"92","author":"Treon","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jbmr.4507","article-title":"Estrogen-responsive gene MAST4 regulates myeloma bone disease","volume":"37","author":"Cui","year":"2022","journal-title":"J. Bone Min. Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib181","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/10428194.2018.1508664","article-title":"Most multiple myeloma patients have low testosterone","volume":"60","author":"John","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib182","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/0008-5472.CAN-04-3079","article-title":"Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib183","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/endrev\/bnab034","article-title":"Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy","volume":"43","author":"Angelidi","year":"2022","journal-title":"Endocr. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.semcancer.2023.04.003_bib184","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib185","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib186","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","article-title":"Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis","volume":"106","author":"Piccoli","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib187","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2005.09.011","article-title":"The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen","volume":"240","author":"Garcia","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2023.04.003_bib188","doi-asserted-by":"crossref","first-page":"f5039","DOI":"10.1136\/bmj.f5039","article-title":"Risk of colorectal cancer after initiation of orlistat: matched cohort study","volume":"347","author":"Hong","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib189","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","article-title":"Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity","volume":"64","author":"Kridel","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2023.04.003_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175456","article-title":"Potential of Orlistat to induce apoptotic and antiangiogenic effects as well as inhibition of fatty acid synthesis in breast cancer cells","volume":"939","author":"Jovankic","year":"2023","journal-title":"Eur. J. Pharm."},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046484","article-title":"Inhibition of fatty acid metabolism reduces human myeloma cells proliferation","volume":"7","author":"Tirado-Velez","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib192","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s12325-020-01591-9","article-title":"Naltrexone's impact on cancer progression and mortality: a systematic review of studies in humans, animal models, and cell cultures","volume":"38","author":"Liubchenko","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib193","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/jpet.112.194159","article-title":"Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo","volume":"342","author":"Mundra","year":"2012","journal-title":"J. Pharm. Exp. Ther."},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib194","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00003495-200868050-00011","article-title":"Bupropion: a review of its use in the management of major depressive disorder","volume":"68","author":"Dhillon","year":"2008","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.semcancer.2023.04.003_bib195","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.mehy.2003.11.032","article-title":"Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma","volume":"62","author":"Kast","year":"2004","journal-title":"Med Hypotheses"},{"issue":"3","key":"10.1016\/j.semcancer.2023.04.003_bib196","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pon.952","article-title":"An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners","volume":"15","author":"Moss","year":"2006","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.semcancer.2023.04.003_bib197","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib198","first-page":"54","article-title":"Inhibitory effect of topiramate on Lewis lung carcinoma metastasis and its relation with AQP1 water channel","volume":"25","author":"Ma","year":"2004","journal-title":"Acta Pharm. Sin."},{"issue":"1\u20133","key":"10.1016\/j.semcancer.2023.04.003_bib199","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2011.04.056","article-title":"The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma","volume":"663","author":"Ma","year":"2011","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2023.04.003_bib200","first-page":"1663","article-title":"Topiramate exhibits anti-tumorigenic and metastatic effects in ovarian cancer cells","volume":"10","author":"Xu","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.semcancer.2023.04.003_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107830","article-title":"The immunomodulatory effects of topiramate on azoxymethane-induced colon carcinogenesis in rats: the role of the inflammatory cascade, vascular endothelial growth factor, AKT\/mTOR\/MAP kinase signaling and the apoptotic markers","volume":"98","author":"Kabel","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"9","key":"10.1016\/j.semcancer.2023.04.003_bib202","article-title":"FDA-approved pharmacotherapy for weight loss over the last decade","volume":"14","author":"Idrees","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.semcancer.2023.04.003_bib203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13679-021-00426-0","article-title":"Gender differences in obesity-related cancers","volume":"10","author":"Argyrakopoulou","year":"2021","journal-title":"Curr. Obes. Rep."},{"issue":"7","key":"10.1016\/j.semcancer.2023.04.003_bib204","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.3390\/ijms24076192","article-title":"Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk","volume":"24","author":"Wilson","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2023.04.003_bib205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SLA.0000000000002525","article-title":"Bariatric surgery and the risk of cancer in a large multisite cohort","volume":"269","author":"Schauer","year":"2019","journal-title":"Ann. Surg."},{"issue":"14","key":"10.1016\/j.semcancer.2023.04.003_bib206","doi-asserted-by":"crossref","first-page":"1118691","DOI":"10.3389\/fendo.2023.1118691","article-title":"Obesity and myeloma: clinical and mechanistic contributions to disease progression","author":"Marques-Mourlet","year":"2023","journal-title":"Front Endocrinol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X23000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:07:29Z","timestamp":1760918849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X23000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":206,"alternative-id":["S1044579X23000615"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.04.003","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity and multiple myeloma: Emerging mechanisms and perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}